Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Padcev (enfortumab vedotin ADC by Year
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International revenues ($M) ($M)
Pfizer Padcev (enfortumab vedotin ADC: $38M in FY2025, up 40.7% from a year earlier.
Where the FY2025 figure comes from
“|| Padcev | 1,940 | 1,588 | 22% | 22% | 1,902 | 1,561 | 22% | 38 | 27 | 42% | 43%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38 | +40.7% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 27 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Pfizer Padcev (enfortumab vedotin ADC ($M), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/padcev-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.